BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

...the Institut National de la Santé et de la Recherche Médicale (INSERM). PEP-Therapy's lead program, DPT-PEP1...
...of closely related cysteine proteases that are expressed in healthy tissues and tumors. Prestat said DPT-PEP1...
...CASP9 to be dephosphorylated. The company published data in PLoS One in 2013 showing that DPT-PEP1...
Items per page:
1 - 1 of 1